Glaukos Co. (NYSE:GKOS) Shares Sold by Peregrine Capital Management LLC

Peregrine Capital Management LLC decreased its holdings in shares of Glaukos Co. (NYSE:GKOS - Free Report) by 97.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,641 shares of the medical instruments supplier's stock after selling 58,368 shares during the quarter. Peregrine Capital Management LLC's holdings in Glaukos were worth $246,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in GKOS. Louisiana State Employees Retirement System lifted its holdings in Glaukos by 0.4% in the 4th quarter. Louisiana State Employees Retirement System now owns 26,700 shares of the medical instruments supplier's stock worth $4,003,000 after buying an additional 100 shares in the last quarter. HighTower Advisors LLC lifted its holdings in Glaukos by 3.3% in the 3rd quarter. HighTower Advisors LLC now owns 3,207 shares of the medical instruments supplier's stock worth $416,000 after buying an additional 103 shares in the last quarter. Values First Advisors Inc. acquired a new position in Glaukos in the 3rd quarter worth $25,000. New York State Teachers Retirement System lifted its holdings in Glaukos by 0.4% in the 3rd quarter. New York State Teachers Retirement System now owns 48,143 shares of the medical instruments supplier's stock worth $6,272,000 after buying an additional 200 shares in the last quarter. Finally, KBC Group NV lifted its holdings in Glaukos by 16.2% in the 3rd quarter. KBC Group NV now owns 1,445 shares of the medical instruments supplier's stock worth $188,000 after buying an additional 201 shares in the last quarter. Institutional investors and hedge funds own 99.04% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Mizuho upgraded shares of Glaukos from a "neutral" rating to an "outperform" rating and upped their target price for the company from $140.00 to $200.00 in a research note on Wednesday. Wells Fargo & Company upped their target price on shares of Glaukos from $153.00 to $160.00 and gave the company an "overweight" rating in a research note on Friday. Citigroup upgraded shares of Glaukos from a "neutral" rating to a "buy" rating and upped their target price for the company from $132.00 to $162.00 in a research note on Wednesday, December 11th. BTIG Research upped their target price on shares of Glaukos from $140.00 to $149.00 and gave the company a "buy" rating in a research note on Tuesday, November 26th. Finally, JPMorgan Chase & Co. upped their target price on shares of Glaukos from $130.00 to $145.00 and gave the company an "overweight" rating in a research note on Tuesday, November 5th. One analyst has rated the stock with a sell rating, one has issued a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, Glaukos has a consensus rating of "Moderate Buy" and a consensus target price of $163.25.

Insiders Place Their Bets

In other news, Director Gilbert H. Kliman sold 10,000 shares of the company's stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $150.28, for a total value of $1,502,800.00. Following the completion of the sale, the director now directly owns 32,336 shares of the company's stock, valued at approximately $4,859,454.08. This represents a 23.62 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Tomas Navratil sold 3,416 shares of the company's stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $147.14, for a total transaction of $502,630.24. Following the completion of the sale, the insider now directly owns 72,437 shares of the company's stock, valued at approximately $10,658,380.18. This represents a 4.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 18,744 shares of company stock worth $2,792,151. Insiders own 6.40% of the company's stock.

Glaukos Stock Performance

NYSE GKOS traded down $31.33 on Friday, hitting $126.03. The stock had a trading volume of 4,139,906 shares, compared to its average volume of 515,602. Glaukos Co. has a one year low of $83.90 and a one year high of $163.71. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19. The stock has a market cap of $6.95 billion, a price-to-earnings ratio of -43.91 and a beta of 1.04. The company's 50-day moving average is $152.75 and its two-hundred day moving average is $139.41.

Glaukos (NYSE:GKOS - Get Free Report) last posted its earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.02). Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. The firm had revenue of $105.50 million during the quarter, compared to the consensus estimate of $100.72 million. On average, analysts expect that Glaukos Co. will post -1.08 earnings per share for the current year.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.